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To obtain more information of the functional domains of the NPC1 protein, the mutational spectrum and the level
of immunoreactive protein were investigated in skin fibroblasts from 30 unrelated patients with Niemann-Pick C1
disease. Nine of them were characterized by mild alterations of cellular cholesterol transport (the “variant” bio-
chemical phenotype). The mutations showed a wide distribution to nearly all NPC1 domains, with a cluster (11/
32) in a conserved NPC1 cysteine-rich luminal loop. Homozygous mutations in 14 patients and a phenotypically
defined allele, combined with a new mutation, in a further 10 patients allowed genotype/phenotype correlations.
Premature-termination–codon mutations, the three missense mutations in the sterol-sensing domain (SSD), and
A1054T in the cysteine-rich luminal loop all occurred in patients with infantile neurological onset and “classic”
(severe) cholesterol-trafficking alterations. By western blot, NPC1 protein was undetectable in the SSD missense
mutations studied (L724P and Q775P) and essentially was absent in the A1054T missense allele. Our results thus
enhance the functional significance of the SSD and demonstrate a correlation between the absence of NPC1 protein
and the most severe neurological form. In the remaining missense mutations studied, corresponding to other disease
presentations (including two adults with nonneurological disease), NPC1 protein was present in significant amounts
of normal size, without clear-cut correlation with either the clinical phenotype or the “classic”/“variant”biochemical
phenotype. Missense mutations in the cysteine-rich luminal loop resulted in a wide array of clinical and biochemical
phenotypes. Remarkably, all five mutant alleles (I943M, V950M, G986S, G992R, and the recurrent P1007A)
definitively correlated with the “variant” phenotype clustered within this loop, providing new insight on the func-
tional complexity of the latter domain.
Introduction
Niemann-Pick type C (NPC [MIM 257220]) disease is
a neurodegenerative lysosomal lipid storage disease,
with autosomal recessive transmission, characterized by
lysosomal/late-endosomal accumulation of endocytosed
unesterified cholesterol (Pentchev et al. 1995; Patterson
et al. 2001). The clinical manifestations of NPC are het-
erogeneous. Most patients have a progressive neurologic
disease, but both age at onset, which ranges from early
Received February 15, 2001; accepted for publication March 28,
2001; electronically published May 1, 2001.
Address for correspondence and reprints: Dr. Marie T. Vanier, La-
boratoire Fondation Gillet-Me´rieux, Batiment 3B, Centre Hospitalier
Lyon-Sud, F-69495, Pierre-Benite Cedex, France. E-mail: vanier@univ-
lyon1.fr or vanier@lyon151.inserm.fr
 2001 by The American Society of Human Genetics. All rights reserved.
0002-9297/2001/6806-0009$02.00
infancy to adulthood, and subsequent course vary (Van-
ier and Suzuki 1996; Patterson et al. 2001). We have
also documented a wide variation in severity of the cel-
lular cholesterol lesion, with typical severe alterations
described as the “classic” biochemical phenotype and
mild alterations as the “variant” phenotype (Vanier et
al. 1991b).
Although the exact location and nature of the traf-
ficking defect(s) are still under investigation (Liscumand
Munn 1999; Blanchette-Mackie 2000; Cruz and Chang
2000; Davies et al. 2000; Ory 2000), substantial ad-
vances have occurred in our knowledge of NPC. Cell-
hybridization studies and linkage analysis (Steinberg et
al. 1994; Vanier et al. 1996) demonstrated the existence
of two complementation groups. NPC1, the disease-
causing gene in 195% of NPC patients, has been located
to 18q11-q12 and is now fully characterized (Carstea
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et al. 1997; Morris et al. 1999). Very recently, a pre-
viously identified gene, HE1, mapped to chromosome
14q24.3, was recognized as the gene mutated in the
minor NPC2 complementation group (Naureckiene et
al. 2000). The finding of identical clinical, cellular, and
biochemical phenotypes in patients belonging to the two
groups (Vanier et al. 1996; Christomanou et al. 2000)
led to the conclusion that both gene products may func-
tion in tandem or sequentially (Vanier et al. 1996; Car-
stea et al. 1997).
The NPC1 cDNA sequence (see Genbank) predicts a
protein of 1,278 amino acids. Topological analysis of
NPC1 has revealed that the protein contains 13 trans-
membrane domains, three large and four small luminal
loops, six small cytoplasmic loops, and a cytoplasmic
tail (Davies and Ioannou 2000). The region located be-
tween amino acid residues 615 and 797 shows strong
homology to the sterol-sensing domain (SSD) identified
in several other integral membrane proteins that re-
spond to endoplasmic reticulum cholesterol (Carstea et
al. 1997). This putative SSD has the same orientation
as those in HMG-CoA reductase and SCAP (sterol reg-
ulatory element binding protein [SREBP] cleavage ac-
tivation protein) (Davies and Ioannou 2000) and ap-
pears to have important functional significance (Watari
et al. 1999). The mature protein appears glycosylated,
with a size of 170–190 kilodaltons (kD) (Higgins et al.
1999; Watari et al. 1999), and there is convincing ev-
idence that NPC1 resides in late endosomes and inter-
acts transiently with lysosomes and the trans-Golgi net-
work (Higgins et al. 1999; Neufeld et al. 1999). A
number of studies point toward a key role for the NPC1
protein in modulating vesicular trafficking of choles-
terol and of glycolipids (Neufeld et al. 1999; Blanchette-
Mackie 2000; Ory 2000; Zhang et al. 2001), but recent
data suggest that NPC1 is a permease acting as a trans-
membrane efflux pump (Davies et al. 2000).
There are still only limited published studies onNPC1
mutations (Carstea et al. 1997; Greer et al. 1998, 1999;
Millat et al. 1999; Yamamoto et al. 1999, 2000). The
mutation prevalent in patients with Acadian Nova Sco-
tian origins (Niemann-Pick type D) was identified as
G992W (Greer et al. 1998), and that prevalent in His-
panic patients from the Upper Rio Grande area of the
United States was identified as I1061T (Millat et al.
1999). The latter allele was further shown to be the
most common NPC1 mutation among individuals of
western European descent (Millat et al. 1999). Greer et
al. (1999) pointed out that a majority of mutations were
clustered in a luminal cysteine-rich loop, highlighting
the potential functional importance of this domain. On
the other hand, the study by Yamamoto et al. (2000),
including mutational and immunoblotting studies, as
well as information on the clinical presentation, dis-
closed a much wider distribution of the mutations. Pre-
liminary results from the present study were presented
in abstract form (Vanier et al. 1999; Vanier and Millat
2000).
Identification of mutations and studies of the mutated
protein in cultured skin fibroblasts of selected patients
with mutations in NPC1 was initiated primarily to ob-
tain more information on functional domains of the
NPC1 protein. Although we attempted to cover the en-
tire spectrum of clinical and biochemical phenotypes,
we were particularly interested in studying two subsets
of patients. Children with infantile neurological onset
invariably showed pronounced cellular cholesterol ab-
normalities (Vanier et al. 1988, 1991a); they clearly cor-
responded to the most severe form of the disease and
therefore were best suited to pinpoint the most critical
regions of the protein. Among patients with other clin-
ical phenotypes, a majority share the same “classic”
biochemical pattern, but about one-fifth showmoderate
alterations of cellular cholesterol trafficking, described
as the “variant phenotype” (Vanier et al. 1991b). The
biochemical subtype has been shown to be constant
within a sibship (Vanier et al. 1991b) and thus is most
likely defined by the genotype. Whether the variant phe-
notype is correlated with alterations of a specific domain
of the protein is not yet known. To address this question,
we have studied patients with late onset showing either
severe or mild cholesterol-trafficking abnormalities.
Since no biochemical marker has been found, so far, to
correlate with a given clinical phenotype, the second
aim of this study has been to evaluate correlations be-
tween genotype and clinical phenotype. Overall, our
findings allow assignment of existing or new allelic com-
binations to specific phenotypes and provide new in-
formation on the functional significance of two partic-
ular domains of the NPC1 protein.
Subjects and Methods
Subjects
Cultured skin fibroblasts were obtained from 30 un-
related NPC patients from various ethnic backgrounds,
including French (13), German (4), British (4), Dutch
(1), Gypsy (1), Tunisian (3), Turkish (2), Pakistani (1),
and African American (1). Close consanguinity was cer-
tain or likely in 10 families. The methods used for di-
agnosis by evaluation of cellular cholesterol by filipin
staining and of LDL-induced cholesteryl ester formation
were those described by Vanier et al. (1991b). Genetic-
complementation analysis was performed prior to mo-
lecular studies to ensure that all patients belonged to the
main (NPC1) complementation group (Vanier et al.
1996). Classification of patients with respect to their
clinical and biochemical characteristics (table 1) was as
proposed by us elsewhere (Vanier et al. 1988, 1991a,
Table 1
Clinical Summary of the 30 Families Included in the Study
Family
Cell
Line
Code
Biochemical
Phenotypea
Clinical
Phenotypeb
Age at
Death
(years)
Age at
Last
Follow-up
(years) Ethnicity Consanguinity
Parents
Available Reference
1 98119 Classic Infantile 2.83 African American No No Dawson et al. 1971
2 80001 Classic A: Infantile 3.83 Gypsy Yes No Vanier et al. 1988,
case 2
B: Infantile 3.33
C: Cholestatic .30
3 87024 Classic A: Infantile 2.58 Tunisian Yes Yes Kanoun et al. 1989
B: Cholestatic .25
4 91029 Classic A: Infantile 5.16 French Yes Yes
B: Infantile 4.92
5 81057 Classic A: Cholestatic .04 French Yes No Vanier et al. 1988,
case 10
B: Infantile 3.16
6 83024 Classic Infantile 5.08 Turkish Likely No
7 83049 Classic Infantile 5.33 French/West Indies No No Vanier et al. 1988,
case 13
8 82052 Classic Infantile 3.5 French No No Vanier et al. 1988,
case 8 Vanier et al.
1999
9 79011 Classic Infantile 5.0 Tunisian No No Vanier et al. 1988,
case 14
10 96115 Classic Severe late infantile 4.50 French/West Indies No Yes
11 82042 Classic Late infantile 5.75 French No No Vanier et al. 1988,
case 16
12 95085 Classic A: No neurological
signs (cardiac
problem) 1.00 Pakistani Yes No
B: Late infantile 6.00
C: Late infantile 5.75
13 90104 Variant Late Infantile 10 German No Yes
14 93094 Classic A: Late infantile 11.66 French No Yes Millat et al. 1999,
family 8
B: Late infantile 8.00
15 91048 Classic A: Juvenile 24 French No Yes Millat et al. 1999,
family 1
B: Juvenile 20
C: Juvenile 20
D: Juvenile 16
16 98009 Classic Juvenile 32 French No No Millat et al. 1999,
family 15
17 90096 Variant A: Juvenile 18 British No Yes
B: Juvenile 24
18 94139 Variant Juvenile 25 British No No
19 92114 Variant A: Juvenile 28 German No No
B: Juvenile 22
20 95070 Variant Juvenile 13 British No No
21 97089 Variant Juvenile 20 Dutch Yes Yes
22 96017 Variant Adult 43.5 French No Yes
23 96157 Classic A: Adult 37 German No No
B: Adult 41
24 90002 Variant Adult without neu-
rological symp-
toms (simple
psychic
structure) 66 German Yes No Fro¨hlich et al. 1990
25 97014 Classic Adult without neu-
rological
symptoms 50 British No No Fensom et al. 1999
26 96084 Classic No neurological
symptoms 7.5 French No Yes
27 91144 Variant No neurological
symptoms 9.0 French No Yes
28 86065 Classic Cholestatic 1.08 Tunisian Yes No Vanier et al. 1988,
case 39
29 97114 Classic Cholestatic .25 Turkish Yes Baumko¨tter et al. 1998
30 97119 Classic Cholestatic .5 French No No
NOTE.—Families 1–25 are listed in order of decreasing severity of neurological phenotypes. Patients 26–30 could not be classified neurologically (too limited
follow-up or early death resulting from liver failure).
a Defined by the degree of severity of alterations of intracellular cholesterol processing (Vanier et al. 1991b).
b Classification of clinical phenotypes by age at onset of neurological symptoms (except for the cholestatic rapidly fatal form) (Vanier and Suzuki 1996).
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Table 2
Sequence of Primers Used for RT-PCR
Primer Sequence (5′r3′)
cDNA
Coordinatesa
NPC-As GAG CCC AAC CAG CCG AAC 51/34
NPC-Aas CCG AAC ATC ACA ACA GAG ACT GAC 234/211
NPC-Bs CCA TTG CCA AAG GAT GGA TAT G 148/169
NPC-Bas GCC TTG TCA TTA CTT GAG GGG G 515/494
NPC-Cs CTA CGT CGG ACA GAG TTT TGC C 438/459
NPC-Cas GCT ACA TGG TGC TGT GAC CTC ATC 717/694
NPC-Ds CAA TGG ACA GGC ACC TTT TAC C 591/612
NPC-Das CCG TTT TCT GTA GCA CCA CAC TG 888/866
NPC-Es GCT TGG ACG CCA TGT ATG TCA TC 791/813
NPC-Eas CCT GAC GAA CAC GCA GTA ATG AAG 1,100/1,077
NPC-Fs CAG CAT TTG AGG GCT GCT TG 986/1,005
NPC-Fas AAG CGG AGG TCC AAA GGG TAC ATC 1,305/1,282
NPC-Gs CAA CCA ATC CAG TTG ACC TCT GG 1,121/1,143
NPC-Gas AGC ACG GAA TGG CTG TTC TG 1,484/1,465
NPC-Hs CAC GAA CTG CAC CAT TTT GAG TG 1,428/1,450
NPC-Has TTG ACA GGG AAG GTA ATC ACA AGG 1,703/1,680
NPC-Is TGT GTT GGG AGG CTA TGA TGA TC 1,635/1,657
NPC-Ias CCT GCG ACA GCT TTT GAT GTG 1,941/1,921
NPC-Js GTG ACA GTG ATG TCT TCA CCG TTG 1,850/1,873
NPC-Jas AGG ATG ACA GGA ACA TAC TGG GAG 2,218/2,195
NPC-Ks CCA GAG AGA TGA ACG TCT TCA AGG 2,127/2,150
NPC-Kas CCC CAA GAG ACT CAC GAA ACA G 2,352/2,331
NPC-Ls CGG GAT TGG CAG TCT TCA TTG 2,291/2,311
NPC-Las TCC ACC ATG TAG GAG TCA TCT GG 2,621/2,599
NPC-Ms AGC ATC GCA GTC CTG AAC AAA G 2,545/2,566
NPC-Mas GAT ATT GTC CAC TCG ACA GCA AGA C 2,886/2,862
NPC-Ns TTT CGA CTG GGT GAA GCC ACA G 2,838/2,859
NPC-Nas GCG TCA ATA AAG TCA GCA GAG GTC 3,161/3,138
NPC-Os AAG TGT GGC AAA GGG GGA CAT G 3,028/3,049
NPC-Oas ACC GAG GTT GAA GAT AGT GTC GTC 3,309/3,286
NPC-Ps ATA GCC AGT AAT GTC ACC GAA ACC 3,181/3,204
NPC-Pas TTC ATG CTC ACC GTG AAC GCT C 3,539/3,518
NPC-Qs AAC CTG GTG ATG AGC TGT GGC ATC 3,466/3,489
NPC-Qas GTA TCG CTC TTC AGT GGC ACA AC 3,801/3,779
NPC-Rs CTC CGT GTT CAG TGG AAT CAC AC 3,588/3,610
NPC-Ras ACA CAG TTC AGT CAG GAT GCC C 3,869/3,848
a Counted from the adenosine residue of the initiation codon.
1991b; Vanier and Suzuki 1996; Millat et al. 1999). In
summary, patients with neurological symptomswere cat-
egorized, by type and age at onset of first neurological
symptoms, as having either a severe infantile form (onset
at age !2 years), a late infantile form (onset at age 3–5
years), a juvenile form (onset at age 15–16 years), or an
adult form (onset at age 116 years). The denomination
“rapidly fatal cholestatic form” was applied to the dis-
ease of patients who died from liver failure in the first
months of life. On the basis of the severity of impairment
in intracellular cholesterol processing in cultured fibro-
blasts (Vanier et al. 1991b), patients were also classified
into either a classic or a variant biochemical phenotype.
The classic phenotype refers to patients with a striking
accumulation of free cholesterol in lysosomes assessed
by filipin staining, together with a severe block in LDL-
induced cholesteryl ester formation. In cells from bio-
chemically variant patients, cholesterol storage may be
evidenced only after challenge with pure LDL, and the
rate of cholesteryl ester formation may not be affected.
Cultured skin fibroblasts or peripheral blood samples
were also available from the parents of 11 patients. Ge-
nomic DNA was obtained from a control population of
95 unrelated unaffected subjects and from 30 additional
patients with mutations in NPC1, of whom 24 showed
a variant biochemical phenotype.
DNA and RNA Isolation
Genomic DNA was isolated from skin fibroblasts or
from whole blood, according to the protocol of Jean-
pierre et al. (1987). Total RNA was extracted from
fibroblasts monolayers using the Trizol reagent (Gibco
BRL).
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Reverse-Transcription and SSCP Analysis
Reverse transcription was performed using the First-
Strand cDNA synthesis kit (Amersham Pharmacia
Biotech) according to the manufacturer’s instructions.
NPC1 cDNA was amplified in 18 overlapping frag-
ments, using primers described in table 2. Each PCRwas
performed in a 20-ml reaction volume containing 0.4 ml
of cDNA, 200 mM of each dNTP, 1.5 mM MgCl2, PCR
buffer, 1 U of EurobioTaq, 4 pmol of each primer, 0.1
ml a[33P]dATP, and 3,000 Ci/mmol (Amersham Phar-
macia Biotech). Two microliters of the radiolabeled PCR
product were mixed with 15 ml stop solution (95% for-
mamide, 10 mMNaOH, 0.25% bromophenol blue, and
0.25% xylene cyanol) and denatured for 5 min at 95C.
The sample was loaded on 0.5# MDE gels (Biowhit-
taker Molecular Applications), with or without 10%
glycerol. Electrophoresis was performed overnight in
0.6# TBE running buffer, either at 20 W at 4C or at
6W at room temperature.
Mutation Analysis
Sequences of PCR products with aberrant SSCP pat-
terns were determined on cDNA and on genomic DNA
using the Thermosequenase cycle sequencing kit, with
primers labeled with g[33P]dATP, 3,000 Ci/mmol (Amer-
sham Pharmacia Biotech). Because of the numerous
known polymorphisms of the NPC1 gene (Morris et al.
1999; Yamamoto et al. 1999, 2000), for each new point
mutation identified, genomic DNA from the patient and
from 95 control samples was amplified using specific
primers. PCR products were laid as a dot-blot on a nylon
membrane (Hybond-N, Amersham Pharmacia Bio-
tech). Membranes were hybridized with either wild-type
or mutated g[33P]dATP labeled oligoprobes. Whenever
possible (table 1), the mutation was also studied in the
parents.
Detection of the P1007A Mutation by Introduction of
an NheI Restriction Site
Genomic DNA was amplified using the sense primer
5′-TTGACCCTGCCTGCGTTC-3′ and the antisense
primer 5′-CTTTGCCACACTTGGGGCT-3′. The 40
PCR cycles each included steps of 45 s at 92C for de-
naturation, at 60C for annealing, and at 72C for ex-
tension. The 126-bp PCR product was digested for 2 h
at 37C by NheI (Roche Diagnostics) and was analyzed
on a 12% polyacrylamide gel. The mutation gave rise
to a 105-bp product.
Western Blot
Western blotting was performed as described by Ya-
mamoto et al. (2000). Pellets from confluent fibroblast
cultures (in MEM or DMEM, supplemented with 10%
fetal calf serum) were homogenized and briefly sonicated
on ice in buffer A (50 mM Tris (pH8.0), 150 mMNaCl,
100 mg/ml PMSF, and 1 mg/ml aprotinin). The lysates
were centrifuged for 20 min at 100,000 rpm (4C).
After centrifugation, the supernatants were discarded.
The pellets were sonicated again with buffer A contain-
ing 0.4% SDS and were centrifuged for 20min at 13,000
rpm. The protein content of the supernatants was de-
termined by the Coomassie Plus Protein Assay Reagent
Kit (Pierce). The lysates (10 mg protein) were subjected
to 7.5% SDS/PAGE. After transfer overnight to nitro-
cellulose membranes (BioRad), NPC1 protein was de-
tected with a polyclonal NPC1 rabbit antibody raised
against a peptide corresponding to a 19–amino acid res-
idues (1256–1274) peptide in the C-terminus of human
NPC1, used at 1:500 dilution. Final detection was done
by chemiluminescence using the ECL detection kit
(Amersham Pharmacia Biotech).
Results
Spectrum of NPC1 Mutations
Analysis of cDNA and genomic DNA from 30 patients
belonging to the NPC1 complementation group led to
the identification of 32 different mutations, 26 of which
were novel. A compendium of the mutant alleles is pre-
sented in table 3, and their location on a model of the
NPC1 protein is represented schematically in figure 1.
The largest number (25) of mutant alleles contained
point mutations that led to single–amino acid substi-
tutions. None of the novel substitutions was found in
the control population of 95 individuals tested. Other
abnormalities included two nonsense mutations, two
1-bp deletions, one 381-bp insertion, one 14-bp dupli-
cation, and one splice mutation. Mutations were widely
scattered and affected all domains of the protein except
for the NPC1 domain in the N-terminal end. Three of
the five frameshift mutations were in the N-terminal lu-
minal loop, leading to complete or near-complete trun-
cation of the protein, and three missense mutations were
located in the putative SSD. Among them, the Q775P
allele was found to be homozygous in one family (5)
and heterozygous in another (20). It was noteworthy
that 11 (i.e., one-third) of the 32 identified mutations
were located on the luminal cysteine-rich loop between
transmembrane domains 8 and 9. Except for a nonsense
mutation, these mutations all resulted in a single–amino
acid substitution.Two different changes of the same nu-
cleotide, G2974C (24) and G2974A (27) were observed,
both resulting in the G992R substitution. Because of our
particular selection of families, the I1061T allele, doc-
umented elsewhere as the most commonNPC1mutation
(Millat et al. 1999), constituted only 7 of the 60 alleles,
but P1007A (Greer et al. 1999) appeared as the second-
most-recurrent allele (4/60) in this study.
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Figure 1 Topology of the mutations identified in 30 patients on an NPC1 protein model and genotype/phenotype correlations. The
schematic NPC1 protein model is drawn as proposed by Davis and Ioannou (2000). The hatched areas indicate the putative transmembrane
domains. The dotted oval frame delimits the SSD. r, Frameshift mutations, all of them observed in patients with a severe infantile neurological
form. , Missense or nonsense mutation definitively associated to a severe infantile neurological form. , missense mutation likely correlated
with a severe infantile neurological form. , Missense mutation definitively correlated with a variant biochemical phenotype. ●, Other missense
mutation.
Correlations between Genotypes and the Classic or
Variant Biochemical Phenotypes
One aim of our study was to pinpoint possible dif-
ferences between mutations associated with the classic
or the variant biochemical phenotypes (severe or mild
impairment of cellular cholesterol trafficking, respec-
tively) on the basis of the observation that the biochem-
ical phenotype was constant within a sibship (Vanier et
al. 1991a). In the homozygous state, all frameshift, splice
or nonsense mutations and a number of missense mu-
tations (M272R, Q775P, D874V, R934Q, A1054T,
I1061T, and C1168Y) led to the classic biochemical phe-
notype (fig. 1 and table 3). This was also the case for
several combinations of two missense mutations (pa-
tients 7, 14, 16, 25, and 30) or of L724P associated with
a frameshift mutation (patient 10) (table 3).
Among the nine patients with the less common variant
phenotype, four were found to carry one P1007A allele,
combined either with I1061T (patients 17, 18, and 19)
or to a nonsense mutation, W1143X (patient 13).
I1061T has definitively been correlated with a classic
phenotype when in the homozygous state (Millat et al.
1999), and one P1007A allele thus appeared sufficient
to maintain some degree of cholesterol trafficking. These
data suggested that the P1007Amutationwas a common
mutant allele associated with the variant biochemical
phenotype.
This hypothesis was confirmed by investigation of
genomic DNA in a total population of 55 patients with
NPC1, using a simple PCR test based on introduction
of an NheI restriction site. The P1007A allele was never
observed in the 22 patients with a classic biochemical
phenotype but constituted 15/66 alleles (22.7%) in the
33 patients studied who had the variant phenotype (9
from the present mutational study and 24 additional
ones).
Four additional mutant alleles could clearly be as-
cribed to a variant phenotype: I943M (patient 21),
V950M (patient 22) and G992R (patient 24) were all
found in the homozygous state, and G986S (patient 20)
was found in combination with Q775P which is clearly
associated with a classic phenotype (patient 5). An in-
triguing observation is that these four mutations, as well
as P1007A, are clustered within a small region of the
cysteine-rich luminal loop between transmembrane do-
mains 8 and 9 (fig. 1).
Correlations between Genotypes and Mutant NPC1
Protein Studied by Western Blot
Selected cell lines with missense mutations, most of
them homozygous or associated with a frameshift mu-
tation, were studied by immunoblotting (fig. 2). The ho-
mozygous 845delT cell line, which gives rise to very early
premature termination of the protein, was tested to es-
tablish the specificity of the affinity-purified polyclonal
antibody, and, as expected, no detectable band was seen
in the region of interest. Normal fibroblasts gave a dou-
ble band of ∼170 and ∼190 kD. Essentially no detectable
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Figure 2 Western blot of NPC1 protein in cultured fibroblasts
from control subjects, 12 patients with NPC1, and 1 patient with
NPC2. A C-terminal affinity-purified polyclonal antibody was used.
Cells from a patient with a 845delT frameshift mutation served as a
negative control. Eight patients with NPC1 had a homozygous mis-
sense mutation (lanes with a single label), and three were compound
heterozygotes (lanes with a dual label). The NPC2 cell line carried a
homozygous E20X mutation of the HE1 gene.
protein was repeatedly found in three cell lines with mis-
sense mutations: homozygous Q775P and L724P, both
located in the SSD, but also A1054T in the cysteine-rich
region. Furthermore, a clearly diminished amount of the
protein was found in cells with the C1168Y mutation.
In all other mutations studied, including the classic
I1061T, a substantial amount of NPC1 protein could be
detected. Definite conclusions about an apparent small
reduction of protein in some mutations are difficult to
draw, since repeated experiments on different cell pellets
could show a variation of at least twofold in levels of
expression of the protein, in both normal cells and mu-
tant cells. We observed that the protein was unstable in
dilute solution, but variations under strict experimental
conditions suggest the influence of yet-undefined factors
that regulate expression of NPC1. Interestingly, NPC2
cells carrying the mutation E20X on the HE1 gene (fig.
2) or another mutation (Yamamoto et al. 2000) invar-
iably showed NPC1 protein levels well above those ob-
served in the control cells.
Correlations with the Clinical Phenotype
The three patients with a frameshift mutation and
premature stop codon (patients 1, 2, and 3) or a non-
sense mutation (patient 4) on both alleles all had an early
neurological onset and a short life span. This was also
the case for all patients with missense mutations for
which immunoblotting revealed a lack of NPC1 protein.
Patients 5 and 6 carried a homozygous missense mu-
tation in the SSD or the cysteine-rich luminal loop, re-
spectively. Patient 10, who had a SSD missense mutation
associated with a splice mutation leading to exon-24
skipping, had a slightly later neurological onset, but the
disease is progressing very rapidly. For patient 8, one
allele carried a mutation in the SSD of an amino acid
conserved in the patched gene, but the second allele re-
mained unidentified. The significantly reduced amount
of NPC1 protein observed in fibroblasts of patient 12,
who had the C1168Y mutation, also correlated with the
relatively severe late-infantile neurological phenotype.
Conversely, the finding of a near-normal amount of
NPC1 protein was of limited predictive value. This pat-
tern was shared by patients with a neurological juvenile
onset (patient 15, I1061T), a neurological adult form
(patient 22, V950M), or a nonneuronopathic adult form
(patient 24, G992R, and patient 25, I1061T/V378A).
On the other hand, correlations could clearly be drawn
concerning the clinical expression of some missense
mutations or combination of missense mutations. The
combination of the two most common alleles, I1061T/
P1007A, was encountered in three families (17, 18, and
19; five patients) and resulted in a juvenile onset of symp-
toms and a significantly slower progression of the disease
than in homozygous I1061T patients. P1007A combined
with a nonsense mutation (patient 13) resulted in a late-
infantile neurological form. Homozygous V950M cor-
responded to an adult onset of neurological symptoms.
Study of two adults with splenomegaly and no neuro-
logical symptoms (patients 24 and 25) led to the con-
clusion that G992R and V378A were responsible for
this atypical mild phenotype. Interestingly, G992R had
only a mild effect on cholesterol trafficking, whereas
V378A was associated with severe biochemical altera-
tions, demonstrating that the block in cholesterol trans-
port does not correlate with clinical severity, as discussed
elsewhere (Vanier et al. 1991b;Vanier and Suzuki 1998).
Future studies should disclose whether correlations
would be tighter with the newly discovered, possibly
more relevant permease function of the NPC1 protein
(Davies et al. 2000).
Patients 26 and 27 are still too young for conclusions
to be drawn about their potential neurological subtyp-
ing. Mutations found in patients 28–30, initially studied
to facilitate prenatal diagnosis, are reported because
M272R and M1142T (which affects an amino acid con-
served in patched) were the only two missensemutations
found in our study in transmembrane domains outside
of the SSD. R934Q was reported elsewhere in associa-
tion with I1061T (Greer et al. 1999). But since the first
affected child in those families died early, of liver failure,
the complete phenotype associated with these mutations
remains unknown.
Discussion
General Distribution of NPC1 Mutations
Although the number of known NPC1 mutations ap-
pears to be ∼100, taking into account data presented by
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seven groups at international meetings (Patterson et al.
2001), few studies have been published except in ab-
stract form. In a survey of 14 Japanese patients with
NPC1, with a majority of late-infantile cases, the 14
missense mutations and one in-frame deletion were
widely distributed on NPC1 cDNA (Yamamoto et al.
1999, 2000). This was at variance with the initial data
on nine patients reported by Carstea et al. (1997), where
most mutations were found to affect the carboxy-ter-
minal third of the protein. A later survey of 13 families
originating from Canada andMaryland, restricted to the
last six NPC1 exons and boundaries, indeed allowed
identification of 20/26 mutant alleles (Greer et al. 1999).
Greer and colleagues further observed that six of the
eight missense mutations found in these patients—
including G992W, which is characteristic of Nova Sco-
tian patients—were clustered in a conserved NPC1-spe-
cific cysteine-rich loop. More recent topological analysis
of the NPC1 protein by Davies and Ioannou (2000) in-
dicated that the most common missense mutation,
I1061T (Greer et al. 1999; Millat et al. 1999), initially
thought to affect a transmembrane domain, also located
to this luminal loop. In the present study, which included
mostly white patients but covered a wider clinical spec-
trum, nearly all domains of the NPC1 protein—except
for the leucine-zipper region—were affected. Eleven of
the twenty-five identified missense mutations and four
frameshift mutations were located in the first two-thirds
of the protein, suggesting that the discrepancy between
previous results in Japanese versus North American pop-
ulations might be explained, in part, by differences in
phenotypes of the patients. Mutagenesis studies indi-
cated that both the leucine-zipper motif and the putative
SSD were particularly critical regions (Watari et al.
1999). Mutations in the SSD have been identified by
Yamamoto et al. (2000) (F703S) and in this report
(M631R, L724P, and Q775P), but no naturally occur-
ring mutations have been reported so far that affect the
NPC1 leucine-zipper domain. In the present study, 14
of the 30 patients showed a proven or almost certain
homozygous mutation, which greatly facilitated estab-
lishment of genotype/phenotype correlations.
Perinatal Liver Disease Independent of the NPC1
Mutation
It is well known that the neonatal, severe cholestatic
form of NPC and neurological forms of the disease may
occur in the same sibship (Vanier et al. 1991a); this is
further illustrated in this study by families 2, 3, and 5.
Most of the published families have shown an associa-
tion with an infantile neurological form (Patterson et al.
2001), but one of the sibs in the family described by
Jaeken et al. (1980) had a neurological juvenile-onset
form. We recently found one patient with fetal hydrops/
ascites to be homozygous for the I1061T mutation (M.
T. Vanier and G. Millat, unpublished data). His affected
elder brother, now 24 years old, presented with the ex-
pected neurological juvenile form (Millat et al. 1999).
Thus, fatal liver disease in a first affected child (patients
28–30) gives no clue as to the possible neurological
course in other sibs, unless the mutations correspond to
a known neurological subtype. Remarkably, the rapidly
fatal neonatal hepatic forms we studied so far all showed
severe alterations of cellular cholesterol trafficking (M.
T. Vanier, unpublished data).
Missense Mutations in SSD as well as Frameshift and
Nonsense Mutations Lead to Absence of Stable NPC1
Protein and Severe Neurological Phenotype
In patient 1, initially described as having “lactosyl-
ceramidosis” (Dawson et al. 1971) and later reclassified
as having NPC (Wenger et al. 1975; Vanier et al. 1988),
a frameshift occurs at the end of the putative signal
peptide. Patients in families 2 and 3 (Vanier et al. 1988;
Kanoun et al. 1989) also have a very early NPC1 ter-
mination caused by a frameshift mutation, whereas
those in family 4 have a nonsense mutation. The very
severe neurological and biochemical phenotype observed
in these families thus is well in line with the nature of
the molecular lesion. The Q775P missense molecular
lesion found for family 5 is of particular interest, both
as the first naturally occurring homozygous mutation
described in the NPC1 SSD (amino acids 615–797) and
because it affects a SCAP-conserved residue. NPC1 pro-
tein (fig. 2) was undetectable both in fibroblasts of this
patient and in those of patient 10, in whom another
SSD-located substitution, L724P, was associated with a
truncation of the C-terminus that should result in ab-
normal targeting of the protein (Watari et al. 1999). In
patient 8, who had aM631R alteration, the second allele
remained unidentified, but this patient also had a very
severe course of the disease. Absence of detectable levels
of NPC1 protein was reported by Yamamoto et al.
(2000) in a Japanese patient with a F703S/S813X com-
bination. Our results are in agreement with those of the
latter authors, who were the first to point out a corre-
lation between absence or near absence of NPC1 protein
and the most severe clinical presentations (Yamamoto
et al. 2000). Conversely, SSD mutants created by site-
directed mutagenesis (Y643S, Y643C, and P691S), stud-
ied after transfection in CT-60 CHO cells, showed the
presence (although in reduced amount) of NPC1 protein
(Watari et al. 1999). Since we obtained similar results
after transfection of Q775P cDNA to mutant FR4 CHO
cells (K. Chikh, G. Millat, C. Tomasetto, K. Ohno, and
M. T. Vanier, unpublished data), a likely explanation
would be that overexpression masks the instability of
the native protein. Brain glycolipids, studied in patients
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1 (Dawson et al. 1972) and 8 (Vanier 1999), showed
striking abnormalities. Taken together, these data clearly
show that mutations affecting the putative SSD of the
NPC1 protein are particularly deleterious, since they
invariably correspond to the most severe neurological
form of the disease.
Most missense alterations located to other regions of
the NPC1 protein also severely affect cholesterol pro-
cessing. A majority have a lesser impact on the stability
of the protein as seen from immunoblotting, and a
varying effect on the clinical picture, as illustrated by
C1168Y (late-infantile neurological onset, patient 12),
I1061T (juvenile neurological onset; Millat et al. 1999),
and V378A, which apparently underlines the nonneu-
rological adult phenotype observed in patient 25.
In spite of the fact that recent data show that NPC1
has an unexpected transmembrane molecular-pump
activity and suggest that it is a permease that can trans-
port certain lipids, but apparently not cholesterol, across
membranes (Davies et al. 2000), studies in patients de-
finitively highlight a key role of the SSD for the in vivo
function of the protein.
Cysteine-Rich Luminal Loop Appears as a Functionally
Complex Domain
Greer et al. (1999) were the first to highlight the func-
tional significance of the cysteine-rich domain on the
basis of mutational studies in patients. This domain has
resemblance to the RING-finger motif regulatory do-
main of protein kinase C. Watari et al. (2000) further
showed that this domain can bind zinc. From the studies
of Greer et al. (1999), Yamamoto et al. (2000), and
ourselves (Millat et al. 1999 and the present work), no
fewer than 16 different missense mutations have already
been ascribed to the cysteine-rich domain, which spans
amino acids 855 through 1098 (Davies and Ioannou
2000). The first mutation identified, G992W, character-
izes patients from Nova Scotia (former Niemann-Pick
type D), with a juvenile onset and slowly progressing
neurological disease (Greer et al. 1998). Despite the fact
that Nova Scotian patients are of Acadian extraction,
G992W has not been found so far in French patients.
We identified two other base alterations on the same
codon, both leading to the G992R substitution. Patient
24, who has isolated splenomegaly (Fro¨lich et al. 1990)
and is homozygous for this mutation, still has no neu-
rological signs of NPC at age 66 years (K. Harzer, un-
published data). Cultured fibroblasts from this patient;
from patient 27, who has G992R and a frameshift mu-
tation on the other allele; and from patients from Nova
Scotia (Byers et al. 1989) all behaved as biochemical
“variants,” leading to the conclusion that codon 992 is
not essential for cholesterol transport. On the other
hand, the most recurrent I1061T mutation, initially de-
scribed by us (Millat et al. 1999) and by Greer et al.
(1999), which constitutes 15%–18% of mutated alleles
in countries like the United Kingdom, France, or the
United States, is correlated with severe alterations of
cholesterol trafficking (the classic phenotype) and a ju-
venile-onset neurological disease. Immunoblotting stud-
ies revealed a quite good level of NPC1 protein in cells
homozygous for both the G992R and I1061Tmutations.
Conversely, the present study has identified the A1054T
mutation, for which no NPC1 protein was detectable,
and which correlated with a severe infantile neurological
onset form (patient 6). Thus, at variance with what was
seen for the SSD, consequences of naturally occurring
missense mutations affecting the cysteine-rich luminal
loop appeared highly variable.
P1007A is a Common Mutated Allele Associated with
the Variant Biochemical Phenotype
One patient homozygous for the P1007A mutation,
categorized as having the biochemically variant phe-
notype, was described by Greer et al. (1999). We found
four additional patients with the variant phenotype in
whom this allele was combined with I1061T or a non-
sense mutation and further showed a high prevalence of
this allele, 22.7%, in a total population of 33 patients
with the variant phenotype. Systematic screening for this
mutation thus appears justified in patients with the var-
iant phenotype.
Seven Variant Mutant Alleles So Far Identified Locate
to the Cysteine-Rich Luminal Loop
From the study of patients with the P1007A and
G992R mutations, we concluded that a single variant
allele apparently leads to a variant phenotype, irrespec-
tive of the nature of the second allele. Apart from
G992W, G992R, and P1007A discussed above, I943M,
V950M, G986S (identified in this report) and V889M
(Yano et al. 1996; Yamamoto et al. 2000) could all be
classified as variant alleles. Although a recent study in
Portuguese patients indicated that some variant muta-
tions may affect another domain (Ribeiro et al., in press),
those reported so far all located to the cysteine-rich loop,
and most of them were clustered within a small region
(codons 943–1007) of this loop. The present observation
suggests that part of the cysteine-rich domain could be
associated with a NPC1 function not tightly associated
with cholesterol trafficking. The NPC1 protein seems to
be implicated in glycolipid transport (Blanchette-Mackie
2000; Zhang et al. 2001), and, since glycolipid abnor-
malities have been found in brain of patients with the
variant phenotype (Martin et al. 1984; Vanier 1999),
more-detailed studies are indicated. Future studies on
the three-dimensional structure of the cysteine-luminal
loop might also provide new insights on the functional
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complexity of this domain. Above all, how variant mu-
tations specifically relate to the molecular-pump activity
of NPC1 recently described by the group of Ioannou
(Davies et al. 2000) is a particularly intriguing question.
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